Microbial and Biochemical Pharmacy —— Pharmacology
current position:
Home - Education - Ph.D. Supervisor - Microbial and Biochemical Pharmacy —— PharmacologyWANG Zhen
Source:
time:2021-11-30
Views:
Name:WANG Zhen
Department:Biochemistry Department
Tel: (8610)63165289
Email: wangzhen@imb.pumc.edu.cn
Education & Research Experience
A. Educational Background
B.S. - Clinical Medicine, Shan Dong Medical College, China, 1997
Ph.D.-Microbial and Biochemical Pharmaceutics, Peking Union Medical College, 2002
B. Academic Positions and Professional Employment
2011-present
Professor, Department of Biochemistry, Institute of Medicinal Biotechnology, PUMC & CAMS, China
2005-2011
Associate Professor, Department of Biochemistry, Institute of Medicinal Biotechnology, PUMC & CAMS, China
2002-2005
Assistant Professor, Department of Biochemistry, Institute of Medicinal Biotechnology, Peking Union Medical College (PUMC) and Chinese Academy of Medical Sciences (CAMS), China
2002-2004
Postdoctoral fellow, Department of Cancer Biology and Pharmacology, Genome Institute of Singapore, Singapore
2006-2008
Postdoctoral fellow, Department of Radiation Oncology, University of Michigan, Ann Arbor, USA
Research Field:
Molecular mechanisms underlying cancer and bone diseases, and drug discovery, development and treatment for the diseases
Research Interests:
We are interested in understanding the role and acting mechanisms of a panel of E3 ubiquitin ligases in cancer and bone diseases, and aim to find out potential drug target for new drug discovery and development to treat these diseases.
Selected publications:
1. Zhao X, Lin S, Li H, Si S*, Wang Z*. Myeloperoxidase controls bone turnover by suppressing osteoclast differentiation through modulating reactive oxygen species level. J Bone Mineral Res. 2021, 36(3):591-603.
2. Lin S, Zhao X, Wang Z*. TANK-binding kinase 1 mediates osteoclast differentiation by regulating NF-kB, MAPK and Akt signaling pathways. Immunology & Cell Biology. 2021, 99(2):223-233.
3. Shen J, Zhan Y, Li H and Wang Z*, Ouabain impairs cancer metabolism and activates AMPK-Src signaling pathway in human cancer cell lines. Acta Pharmacologica Sinica. 2019, i0:1-9.
4. Shen J, Li P, Shao X, Yang Y, Liu XJ, Feng M, Yu Q, Hu R*, Wang Z*. The E3 ligase RING1 targets p53 for degradation and promotes cancer cell proliferation and survival. Cancer Research. 2018;78(2):359-371.
5. Sha MQ, Zhao XL, Li L, Li LH, Li Y, Dong TG, Niu WX, Jia LJ, Shao RG, Zhen YS, Wang Z*. EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells. Cell Death Dis. 2016, 24;7(11):e2486.
6. Sha M, Mao G, Wang G, Chen Y, Wu X, Wang Z*. DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis. Acta Pharmaceutica Sinica B. 2015; 5(3):188-193.
7. Wang Y, Zhan Y, Xu R, Shao R, Jiang J*, Wang Z*. Src mediates extracellular signal-regulated kinase 1/2 activation and autophagic cell death induced by cardiac glycosides in human non-small cell lung cancer cell lines. Molecular Carcinogenesis. 2015;54 Suppl 1:E26-34.
8. Ji X, Xue S, Zhan Y, Shen J, Wu L, Jin J, Wang Z*, Li Z*. Design, synthesis and antiproliferative activity of a novel class of indole-2-carboxylate derivatives. European Journal of Medicinal Chemistry. 2014, 83C:409-418.
9. Wang Y, Qiu Q, Shen JJ, Li DD, Jiang Xuejun, Si Suyi, Shao RG, Wang Z*. Cardiac glycosides induce autophagy in human non-small cell lung cancer cells through regulation of dual signaling pathways. International Journal of Biochemistry & Cell Biology. 2012, 44:1813-1824.
10. Wang Z, Zheng M, Li Z, Li R, Jia L, Xiong X, Southall N, Wang S, Xia M, Austin CP, Zheng W, Xie Z, Sun Y*. Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition. Cancer Research. 2009, 69(16): 6556-6564.
Awards and Honors
2013, CHPHARS-SERVIER Young Investigator Award in Pharmacology, Chinese Pharmacological Society;
2009, CPA-Sanofi-Aventis Young Investigator Award in Biological drugs, Chinese Pharmaceutical Association;
2005, Beijing Science and Technology Award;
2004, New Star of Science and Technology, Beijing, China
Academic Appointments
2013-present, Member of Committee of Anti-Cancer Agent, Chinese Anti-cancer Association;
2018-present, Member of youth Committee of Chinese Anti-cancer Association;
2009-present, Member of Aging and Anti-aging Association, Gerontological Society of China;
2007-present, Active Member of AACR